Ovarian Hyperstimulation Syndrome clinical trials
The registry lists 62 studies for Ovarian Hyperstimulation Syndrome across more than 10 countries. 2 are recruiting or about to start. 44 of them are mainly about Ovarian Hyperstimulation Syndrome (how this is decided). Per ClinicalTrials.gov, last updated 2026-08-21.
Get an email when these change. Save the Ovarian Hyperstimulation Syndrome studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Merck KGaA, Darmstadt, Germany (3) · Instituto Valenciano de Infertilidad, IVI VALENCIA (3) · Royan Institute (3) · Eugonia (2) · Ferring Pharmaceuticals (2) · Chenshiling (2) · First Affiliated Hospital, Sun Yat-Sen University (2) · UConn Health (2)
What is being tested here
Drugs under test in Ovarian Hyperstimulation Syndrome studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Letrozole | 1 | 1 | 2 |
| Dexamethasone | 1 | 1 | 2 |
| Chorionic Gonadotropin | 0 | 0 | 6 |
| Triptorelin | 0 | 1 | 6 |
| Cabergoline | 0 | 2 | 4 |
| Progesterone | 0 | 0 | 2 |
| Gonadotropin Releasing Hormone Antagonist | 0 | 1 | 2 |
| Cetrorelix | 0 | 0 | 2 |
| Quinagolide | 0 | 0 | 2 |
| Inositol | 0 | 0 | 1 |
Drug classes tested here Corticosteroids 1 open · Dopamine agonists 7
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
Who these studies take
Of the 1 Ovarian Hyperstimulation Syndrome studies recruiting now, 0 (0%) set no upper age limit and 1 (100%) stop at 75 or younger. 0 (0%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 0 (0%) | 0 (0%) |
| 18 | 1 (100%) | 1 (100%) |
| 30 | 1 (100%) | 1 (100%) |
| 40 | 1 (100%) | 1 (100%) |
| 50 | 0 (0%) | 0 (0%) |
| 65 | 0 (0%) | 0 (0%) |
| 75 | 0 (0%) | 0 (0%) |
| 85 | 0 (0%) | 0 (0%) |
Across all 62 studies, recruiting or not: 94% stop at 75 or younger and 94% at 65; 5% take children; 95% are for women only and 0% for men only; 35% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 50 of 62. Browse all 62 → or search them.
- Real-world Evidence on Follitropin Delta Individual DosingRecruitingNCT051735971 country
- The Letrozole Administration During Luteal PhaseNot yet recruitingNCT02686151Phase 31 country
- Myo-Inositol for Ovarian Stimulation and ICSI Outcomes in Women With PCOSCompletedNCT07779850Not applicable1 country
- Comparative Study Between Calcium Gluconate With Diosmin, Cabergoline and Cabergoline With DiosminCompletedNCT06333691Not applicable1 country
- Freeze All Strategy Versus Fresh Embryo Transfer After GnRH Analogue TriggerCompletedNCT05362734
- Dual Trigger" in IVF Patients at High Risk of Ovarian Hyper Stimulation SyndromeActive, not recruitingNCT05638529Phase 41 country
- Association Between Live Birth Rate and Serum Progesterone During Hormonal Replacement TherapyCompletedNCT055886351 country
- Montelukast for Prevention & Treatment of OHSSSuspendedNCT03794037Phase 21 country
- Ovarian Hyperstimulation Syndrome Using Calcium InfusionStatus unknownNCT05198128Not applicable
- The Four Methods of Ovarian Stimulation in Patients With Polycystic Ovarian SyndromeCompletedNCT03876145Not applicable1 country
- Gonadotropin Releasing Hormone Agonist (GnRHa) Versus Estrogen and Progesterone for Luteal Support in High RespondersStatus unknownNCT04797338Phase 41 country
- Luteal Phase Supplementation With Recombinant LH After GnRh Agonist Oocytes Triggering in Women at Risk of OHSSCompletedNCT022009521 country
- Medical Assistance for the Procreation and Risk of Thrombosis.TerminatedNCT026106081 country
- Management of Ovarian Hyperstimulation Syndrome as a State of Defective Mineralocorticoid ResponseCompletedNCT04351126Phase 21 country
- Comparison of Clinical Outcomes Between IVM and Minimal Stimulation IVF in Patients With PCOSStatus unknownNCT03134482Not applicable1 country
- Coasting Versus Antagonist Protocol in Patients at High Risk of OHSSCompletedNCT03996434Phase 41 country
- Ovarian Hyperstimulation Syndrome in Patients Triggered by GnRH Agonist for Excessive Follicular ResponseTerminatedNCT02701452Not applicable
- Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte MaturationTerminatedNCT01606709Phase 41 country
- Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSSCompletedNCT01815138Phase 41 country
- Study of Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in In Vito Fertilization Cycles and Derivation of OHSS BiomarkersCompletedNCT01535859Phase 31 country
- The Influence of Timing of Cabergoline Initiation on Prevention of OHSSStatus unknownNCT02620605Phase 31 country
- Preventive Application of GnRH Antagonist on Early OHSSStatus unknownNCT03188471Phase 41 country
- Controlled Ovarian Stimulation by HP-hMG for IVF / ICSI Cycles: Study on Ovarian Hyper Stimulation Syndrome in a Cohort of Women From 18 to 36 Years Old.CompletedNCT017037281 country
- Clinical Study of Recombinant Human Follitropin for Injection Assisted in COH Assisted IVF-ETStatus unknownNCT03071172Phase 31 country
- Endometrial Receptivity After GnRH Agonist TriggeringCompletedNCT01500863Phase 41 country
- Low-dose Gonal-f® in Ovulation InductionTerminatedNCT01871532Phase 42 countries
- Efficacy and Safety of Dexamethasone Prevention for Patients of Ovarian Hyperstimulation SyndromeStatus unknownNCT02846493Phase 21 country
- Comapring Luteal Phase Support in IVF Patients Who Are at High Risk for Developing OHSSStatus unknownNCT02827656Not applicable
- The Effect of a Dual Trigger on Intracytoplasmic Sperm Injection (ICSI) Reproductive OutcomesWithdrawnNCT01979341Not applicable1 country
- Administration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian Hyperstimulation Syndrome( OHSS)WithdrawnNCT01109888Phase 1/2
- Preventive Application of Letrozole Decrease Incidence of Early Onset of OHSSCompletedNCT02670304Phase 4
- Short Versus Long Protocol for IVF and IVF+ICSICompletedNCT00756028Phase 41 country
- Transfer of Fresh Versus Frozen/Thawed Embryos in IVF Cycles Where GnRH Agonist is Utilized for Oocyte Maturation.WithdrawnNCT00365027Not applicable
- Can GnRH Agonist Trigger Prevent Ovarian Hyperstimulation Syndrome?TerminatedNCT01714648Phase 41 country
- Compare the Efficacy of Human Albumin With Cabergoline to Prevent Ovarian Hyper Stimulation in Assisted Reproductive Technology (ART) ProgramCompletedNCT01009567Phase 1/21 country
- Monitoring the Early Follicular Phase With Androstenedione in Low-dose Step-up Ovulation Induction in High RespondersStatus unknownNCT023294831 country
- Luteal Antagonist Versus Conventional Treatment in Women With Severe Early Ovarian Hyperstimulation Syndrome (OHSS)Status unknownNCT02392520Not applicable1 country
- Response of VEGF and AT-II to HCG in PCOSCompletedNCT02265861Early Phase 1
- Corifollitropin Alfa Application in PCOS PatientsStatus unknownNCT02215135Phase 41 country
- Study of Serum Levels of Oxidative Stress Markers in Ovarian Hyperstimulation PatientsStatus unknownNCT022022781 country
- A Prospective, Multi-centric Observational Study to Determine the Mono-bifollicular Development in Infertile Women Subjected to Ovulation Induction With Follitropin αCompletedNCT011110841 country
- Calcium for Prevention of Ovarian Hyperstimulation SyndromeCompletedNCT01427335Phase 31 country
- An Observational Study to Compare the Dose of Gonal-fTM FbM Prescribed by the Doctor With the Recommendation of the Dose Calculator Consort and to Evaluate the Ease of Use of Pre-filled Pen of Gonal-fTM FbM PenTerminatedNCT010807291 country
- Long Acting GnRH Antagonist in PCOS Women Undergoing IVFStatus unknownNCT020849401 country
- Dual Trigger to Reduce Ovarian Hyperstimulation SyndromeStatus unknownNCT02022228Not applicable1 country
- Repeated Injection of GnRH Agonist to Reduce Ovarian Hyperstimulation SyndromeStatus unknownNCT02022241Not applicable1 country
- Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist CyclesCompletedNCT00627406Phase 41 country
- GnRH Antagonist for Treatment of Early Ovarian Hyperstimulation SyndromeCompletedNCT01268761Phase 31 country
- The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in Oocyte DonorsCompletedNCT00867659Not applicable1 country
- Ovarian Hyperstimulation Syndrome (OHSS) Prevention With AgonistCompletedNCT008355231 country